# ABBV-706

Source: https://onco.cc/drugs/abbv-706/  
OnCo record `abbv-706` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ABBV-706 is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

ABBV-706 is an antibody-drug conjugate developed by AbbVie. The sponsor describes its target as SEZ6 (seizure-related homolog 6), which OnCo does not yet have a target page for. The sponsor states: ABBV-706 is described as a targeted antibody-drug conjugate; a trial exclusion criterion barring prior SEZ6-targeted ADC use indicates it targets SEZ6, given intravenously in small cell lung cancer, alone or combined with atezolizumab. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07365241, plans to enrol 531 participants with primary completion expected 2030-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: ABBV-706 is described as a targeted antibody-drug conjugate; a trial exclusion criterion barring prior SEZ6-targeted ADC use indicates it targets SEZ6, given intravenously in small cell lung cancer, alone or combined with atezolizumab.

## Sources

- ClinicalTrials.gov: trials of ABBV-706: https://clinicaltrials.gov/search?intr=ABBV-706

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)
- trials: [A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer](https://onco.cc/trials/nct07365241/), [A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St](https://onco.cc/trials/nct07155174/)

---
JSON: https://onco.cc/api/v1/entities/abbv-706.json